Nuvalent Inc.
07/21/2025 | Press release | Distributed by Public on 07/21/2025 04:33
Material Event (Form 8-K)
Item 8.01 Other Events.
On July 21, 2025, Nuvalent, Inc. announced the initiation of ALKAZAR, its Phase 3 clinical trial evaluating neladalkib for TKI-naïve patients with advanced ALK-positive non-small cell lung cancer, versus ALECENSA®, a front-line standard of care, with the dosing of the first patient in the trial.
Nuvalent Inc. published this content on July 21, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on July 21, 2025 at 10:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io